Aldosterone inhibition in patients with heart failure with preserved ejection fraction

JAMA

Volumn 310, Issue 2, 2013, Pages 205-

  Lund, Lars H ^a   Stah̊lberg, Marcus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LETTER; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; DIASTOLIC HEART FAILURE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; NOTE;

FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; VENTRICULAR FUNCTION, LEFT;

EID: 84880143730     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.7967     Document Type: Letter

References (5)

1. Edelmann F, Wachter R, Schmidt AG, et al Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781-791.
2. Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-2467.
3. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-2345. (Pubitemid 44453578)
4. Abraham WT, Fisher WG, Smith AL, et al MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845- 1853. (Pubitemid 34603028)
5. Lund LH, Benson L, Dahlström U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308(20):2108-2117.